Xeris Pharmaceuticals | XERS - Current Assets


Xeris Pharmaceuticals reported $251.68M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Celltrion KRW 481.57B 10.97B Mar/2026
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 897.54M 222.37M Jun/2026
Divis Laboratories Ltd INR 110.96B 12.53B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Kangmei Pharma CNY 6.8B 225.83M Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Organigram Holdings CAD 250.09M 6.46M Mar/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pacira USD 615.21M 100.25M Jun/2026
Perrigo USD 2.71B 85M Mar/2026
Pharma Mar EUR 280.95M 7.5M Jun/2026
Qiagen NV USD 1.54B 454.82M Mar/2026
Sartorius EUR 1.64B 280M Jun/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.02B 652.12M Mar/2026
Zz Pientze Pharmaceu CNY 11.43B 728.95M Mar/2026